Psychosis of Parkinson's disease: Serotonin 2A receptor inverse agonists as potential therapeutics

Current Opinion in Investigational Drugs

Volumn 4, Issue 7, 2003, Pages 815-819

  Weiner, David M ^a,b,c   Vanover, Kimberly E ^a   Brann, Mark R ^a,c   Meltzer, Herbert Y ^d   Davis, Robert E ^a  

^a ACADIA PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Clozapine; Inverse agonist; Parkinson's disease; Psychosis; R SAT; Serotonin 2A receptor

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE; ERGOLINE DERIVATIVE; HISTAMINE H1 RECEPTOR; KETANSERIN; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; SEROTONIN 2 AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2A RECEPTOR INVERSE AGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; BLOOD DYSCRASIA; CLINICAL TRIAL; DISEASE EXACERBATION; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; MYOCARDITIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMISSION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TREMOR; VISUAL HALLUCINATION; WEIGHT GAIN;

ANIMALS; HUMANS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS;

EID: 0142094608     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Lang AE, Lozano AM: Parkinson's disease. N Eng J Med (1998) 339(15):1044-1053.
2. Schoenberg BS, Anderson DW, Haerer AF: Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology (1985) 35(6):841-845.
3. De Rijk M, Tzourio C, Breteler M, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA: Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's Disease. J Neurol Neurosurg Psychiatry (1997) 62(1):10-15.
4. Friedman JH: The management of the levodopa psychoses. Clin Neuropharmacol (1991) 14(4):283-295.
5. Factor SA, Molho ES, Podaskalny GD, Brown D: Parkinson's Disease: Drug-Induced Psychiatric States. In: Behavioral Neurology of Movement Disorders. Weiner WJ, Lang AE (Eds), Advances in Neurology, Raven Press Ltd, New York, NY, USA (1995) 65:115-138.
6. Goetz C: Hallucinations in Parkinson's disease: The clinical syndrome. In: Parkinson's Disease: Advances in Neurology. Stern GM (Ed), Lippincott Williams and Wilkins, Philadelphia, PA, USA (1999) 80:419-423.
7. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revised. American Psychiatric Association Press, Washington, DC, USA (2000):342-343.
8. Celesia GG, Barr AN: Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol (1970) 23(3):193-200.
9. Jenkins RB, Groh RH: Mental symptoms in parkinsonian patients treated with L-dopa. Lancet (1970) 2(665):177-179.
10. Goodwin FK: Psychiatric side effects of levodopa in man. J Am Med Assoc (1971) 218(13):1915-1920.
11. Sanchez-Ramos JR, Ortoll R, Paulson GW: Visual hallucinations associated with Parkinson disease. Arch Neurol (1996) 53(12):1265-1268.
12. Inzelberg R, Kipervasser S, Korczyn AD: Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry (1998) 64(4):533-535.
13. Aarsland D, Larsen JP, Cummings JL, Laake K: Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: A community-based study. Arch Neurol (1999) 56(5):595-601.
14. Fenelon G, Mahieux F, Huon R, Zeigler M: Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain (2000) 123(Pt 4):733-745.
15. Holroyd S, Currie L, Wooten GF: Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2001) 70(6):734-738.
16. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology (1993) 43(11):2227-2229. This study demonstrates the dramatic impact that the development of psychoses has on patients with PD. Psychosis represents a major risk factor for loss of independence and subsequent institutionalization.
17. Aarsland D, Larsen JP, Tandberg E, Laake K: Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. J Am Geriatr Soc (2000) 48(8):938-942.
18. Goetz CG, Stebbins GT: Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology (1995) 45(4):669-671.
19. Friedman JH, Factor SA: Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord (2000) 15(2):201-211. This review concisely covers the clinical syndrome and focuses on currently available treatment options, highlighting the paucity of safe and effective agents.
20. Molho ES, Factor SA: Parkinson's disease: The treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep (2001) 1(4):320-328.
21. Factor SA, Brown D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord (1992) 7(2):125-131.
22. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB: Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology (2001) 57(11):2078-2082.
23. Scholtz E, Dichgans J: Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci (1985) 235:60-64. This study represents the first report of the use of clozapine to treat psychosis in PD patients.
24. Friedman JH, Max J, Swift R: Idiopathic Parkinson's disease in a chronic schizophrenic patient: Long-term treatment with clozapine and L-dopa. Clin Neuropharmacol (1987) 10(5):470-475.
25. Friedman JH, Lannon MC: Clozapine in the treatment of psychosis in Parkinson's disease. Neurology (1989) 39(9):1219-1221.
26. The Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Eng J Med (1999) 340(10):757-763. This study represents the first controlled trial demonstrating the efficacy and tolerability of an antipsychotic agent in PD patients. Clozapine had a high potency effect in this patient population, with excellent motoric tolerability.
27. The French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson's disease. Lancet (1999) 353(9169):2041-2042.
28. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I: Clozapine and agranulocytosis. Lancet (1975) 2(7935):611.
29. Clozaril. Prescribing Information. Novartis Pharmaceutical Corporation (2002):1-24.
30. Baldessarini RJ, Frankenburg FR: Clozapine. A novel antipsychotic agent. N Engl J Med (1991) 324(11):746-754.
31. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL: Olanzapine in the treatment of dopaminomimetics psychosis in patients with Parkinson's disease. Neurology (1996) 47(4):1085-1087.
32. 2 receptor antagonist activity in this respect.
33. Factor SA, Molho ES, Friedman JH: Risperidone and Parkinson's disease. Mov Disord (2002) 17(1):221-222.
34. Fernandez HH, Friedman JH, Jacgues C, Rosenfeld M: Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord (1999) 14(3):484-487.
35. Fernandez HH, Trieschman ME, Burke MA, Friedman JH: Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry (2002) 63(6):513-515.
36. Reddy S, Factor SA, Molho ES, Feustel PJ: The effect of quetiapine on psychosis and motor function in Parkinsonian patients with and without dementia. Mov Disord (2002) 17(4):676-681.
37. Everett GM, Borcherding JW: L-dopa: Effect on concentration of dopamine, norepinephrine and serotonin in brains of mice. Nature (1970) 168(933):847-850.
38. Butcher L, Engel J, Fuxe K: L-dopa-induced changes in central monoamine neurons after peripheral decarboxylase inhibition. J Pharm Pharmacol (1970) 22(4):313-316.
39. Ng KY, Chase TN, Colburn RW, Kopin IJ: L-dopa-induced release of cerebral monoamines. Science (1970) 170(953):76-77.
40. Birkmayer W, Danielczyk W, Neumayer E, Riederer P: Nucleus ruber and L-dopa psychosis: Biochemical post-mortem findings. J Neural Transm (1974) 35(2):93-116.
41. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA et al.: 5-Hydroxytryptamine 2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther (2001) 299(1):268-276.
42. 2, receptor subtypes. J Pharmacol Exp Ther (2002) 303(2):815-822.
43. Factor SA: Parkinson's disease: Initial treatment with levodopa or dopamine agonists. Curr Treat Options Neurol (2001) 3(6):479-493.
44. 2 receptors: Implications for treating LSD-induced hallucinogenesis. Psychopharmacology (1989) 98(4):495-499.
45. Liechti ME, Geyer MA, Hell D, Vollenwieder FX: Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology (2001) 24(3):240-252. This study, along with reference [46], demonstrates the power that clinical pharmacological studies of hallucinogens in normal volunteers have to begin to dissect the molecular basis of drug action in vivo. The authors combine sensitive physiological measures with brain imaging to define the anatomy and pharmacology of hallucinosis.
46. 15O]-PET in healthy humans. Neuropsychopharmacology (2000) 23(4):388-395. This study, along with reference [45], demonstrates the power that clinical pharmacological studies of hallucinogens in normal volunteers have to begin to dissect the molecular basis of drug action in vivo. The authors combine sensitive physiological measures with brain imaging to define the anatomy and pharmacology of hallucinosis.
47. Leysen JE, Niemegeers CJ, Tollenaere JP, Laduron PM: Serotonergic component of neuroleptic receptors. Nature (1978) 272(5649):168-171.
48. 2A receptor affinity as being a critical component of the clinical atypical nature of an antipsychotic, and has significantly influenced the design of novel agents in this therapeutic class.
49. Meltzer HY, Kennedy J, Dai J, Parsa M, Riley D: Plasma clozapine levels and the treatment of L-dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine. Neuropsychopharmacology (1995) 12(1):39-45.
50. 2 receptors.
51. 2 receptors.
52. Ikeguchi K, Kuroda A: Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci (1995) 244(6):320-324.